
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience demonstrates a strong positive outlook primarily due to the advancements in its clinical assets, particularly ALTO-207 (CTC-501), which has shown improved tolerability against pramipexole, resulting in the capability for higher dosing and faster titration, potentially enhancing treatment outcomes for depressive symptoms. The company's recent financial performance is notable, with ALTO-207 generating $1.08 billion in revenue for FY24, reflecting a significant increase of approximately 60% compared to FY23. Additionally, the development of a new transdermal formulation for ALTO-101 is expected to enhance its safety profile and systemic exposure, further supporting ongoing studies and increasing confidence in the overall precision psychiatry pipeline.
Bears say
Alto Neuroscience Inc has faced significant headwinds since its IPO in 2024, primarily due to the failure of its lead asset, ALTO-100, in a critical Phase 2b study targeting major depressive disorder, compounded by negative data from ALTO-300. The failure of ALTO-100 raises serious concerns about the efficacy of the company's approach, particularly given the linkage between cognitive deficits in patients and poorer treatment outcomes, which may hinder future advancements. Despite ongoing studies in bipolar depression, the overall outlook remains bleak as previous clinical readouts have disappointed, suggesting a low probability of success for current and future assets.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares